# Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

> **NCT00737438** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan

## Key facts

- **NCT ID:** NCT00737438
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-02-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00737438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00737438, "Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00737438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*